Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
cDMARD
DRUG
2 trials
Sponsors
Eli Lilly and Company
Conditions
Rheumatoid Arthritis
Phase 3
A Moderate to Severe Rheumatoid Arthritis Study
Completed
NCT01721044
Eli Lilly and Company
Rheumatoid Arthritis
Start: 2013-01-31
End: 2014-09-30
Updated: 2019-09-18
A Study in Moderate to Severe Rheumatoid Arthritis Participants
Completed
NCT01721057
Eli Lilly and Company
Rheumatoid Arthritis
Start: 2012-12-31
End: 2014-12-31
Updated: 2019-09-18
Related Papers
Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis up to 6.5 years of treatment: results of a long-term study.
2024-10-01
4 citations
P127 Baricitinib Efficacy in Moderate Rheumatoid Arthritis - A Post-hoc Analysis from two Phase III Trials
Lara D. Veeken
2023-04-01
Relative Impact of Pain and Disease Activity on Improvements in Fatigue
JCR Journal of Clinical Rheumatology
2022-12-06
2 citations
Maintenance of Patient-Reported Outcomes in Baricitinib-Treated Patients with Moderate-to-Severe Active Rheumatoid Arthritis: Post Hoc Analyses from Two Phase 3 Trials.
2022-01-06
3 citations
Pain Reduction in Rheumatoid Arthritis Patients Who Use Opioids: A Post Hoc Analysis of Phase 3 Trials of Baricitinib
ACR Open Rheumatology
2021-12-16
7 citations
Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database.
2021-10-27
107 citations
Radiographic Progression of Structural Joint Damage Over 5 Years of Baricitinib Treatment in Patients With Rheumatoid Arthritis: Results From RA-BEYOND
The Journal of Rheumatology
2021-09-15
7 citations
Efficacy of Long-Term Treatment with Once-Daily Baricitinib 2 mg in Patients with Active Rheumatoid Arthritis: Post Hoc Analysis of Two 24-Week, Phase III, Randomized, Controlled Studies and One Long-Term Extension Study.
2021-05-24
2 citations
The Janus kinase 1/2 inhibitor baricitinib reduces biomarkers of joint destruction in moderate to severe rheumatoid arthritis.
2020-10-12
15 citations
Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis
Arthritis Research & Therapy
2020-05-15
16 citations
Use of daily electronic patient-reported outcome (PRO) diaries in randomized controlled trials for rheumatoid arthritis: rationale and implementation.
2019-03-22
35 citations
Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials
Modern Rheumatology
2019-02-20
54 citations
Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment
The Journal of Rheumatology
2018-09-15
251 citations
Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs in United States and Rest of World: A Subset Analysis
Rheumatology and Therapy
2018-04-21
5 citations
Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies.
2018-02-20
44 citations
Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics.
2018-01-13
9 citations
Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis
Lara D. Veeken
2018-01-05
58 citations
Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis
RMD Open
2017-03-01
42 citations
Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON).
2016-10-31
72 citations
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study.
2016-09-29
272 citations
1 more papers not shown